SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Maul Coin

Maul Coin is trending as the community rallies behind the developer's transparent, hands-on approach to building a long-term project and overcoming liquidity challenges. While some skeptics voice concerns about typical small-cap volatility and the lack of a chart, holders are actively pushing the token across social platforms and DEX aggregators in anticipation of future growth.

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Wayne, PA.

Avalo Therapeutics Inc

Avalo Therapeutics is attracting significant attention as investors monitor its lead clinical candidate, AVTX-009, with the community actively discussing potential Phase 2 trial readouts and bullish analyst coverage that underscores its long-term upside. Market participants are closely watching the high trading volume and volatility, while simultaneously expressing caution over the companys ongoing capital requirements and historical dependence on successful clinical data.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as community members rally behind its recent integration with the Stellar ecosystem for stablecoin payroll and speculate on upcoming major partnership announcements. Investors are actively discussing the project's utility and long-term potential, leading to a surge in active wallet holders and heightening anticipation for potential developments at industry events.

WorldFinancial

World Financial (WLFI) is experiencing significant volatility and heavy selling pressure as the community reacts to a congressional probe into its foreign investment dealings and potential conflicts of interest. While some traders view the price dip as a high-conviction buying opportunity supported by institutional interest and upcoming product milestones, others are actively debating whether the project is a long-term utility play or a speculative "pump and dump" scheme linked to political figures.

Derive is a decentralized protocol that creates programmable onchain options, perpetuals, and structured products.   Derive is deployed and operates on Derive Chain, an Ethereum rollup built using the OP stack and is the home of the Derive Protocol. It is a permission-less smart contract platform.  The Derive DAO earns trading fees from the Derive Protocol and gas fees from the Derive Chain, governed by DRV token holders. Trading fees accrue to an insurance fund to foster robustness of the protocol and rollup.  Derive has built an AI-powered trading app built for pro traders. In collaboration with Messari, Derive Pro translates market views into trades. The agent then prepares transactions for users and leverages smart contract wallets to make trades one-click, gasless and chainless. The app will support spot, perps and options trading on Derive, and will also plug in to spot AMMs on L2s like Optimism, Arbitrum and Base.

Derive

Derive is generating buzz following its collaboration with Synthetix to build derivatives on Ethereum, fueling optimism among holders regarding potential protocol growth. Community members are actively tracking the token's technical strength and buyback mechanisms as the asset displays steady upward momentum.

BNB is the native utility token of the BNB Chain ecosystem, acting as a multi-chain asset that powers decentralized applications and facilitates value exchange across its network. It serves as the primary asset for paying transaction gas and smart contract deployment fees while providing users with tiered fee discounts on the Binance exchange. The project’s main value proposition lies in its unified multi-chain architecture, which integrates a smart contract platform, a Layer 2 scaling solution, and a decentralized data storage network into a cohesive settlement and data availability layer.  The network operates on a Proof of Staked Authority consensus mechanism, utilizing a group of 21 active validators known as the Cabinet to verify transactions and produce blocks every 3 seconds. Validators are elected daily based on the amount of BNB staked or delegated to them, and the system employs fast finality and slashing penalties to maintain security and integrity. To manage its long-term economy, the project uses a programmatic dual-burn strategy that permanently removes tokens through real-time fee destruction and quarterly buybacks.  Launched in 2017 by the Binance platform, the project initially distributed 50% of its 200 million token supply to the public, while the founding team received 40% and angel investors were allocated 10%. Though it began as a token on the Ethereum network, it eventually migrated to its own autonomous architecture that remains fully compatible with the Ethereum Virtual Machine. Today, the token's utility includes paying for network gas, participating in staking rewards, and enabling decentralized governance through which holders can vote on technical upgrades and economic changes.

Binance

Binance is trending as investors monitor shifting institutional sentiment and ongoing legal developments, while community members actively debate the platform's liquidity, security measures, and the potential impact of broader regulatory clarity in the crypto market.

WhiteFiber, Inc. provides AI and HPC infrastructure & cloud and data center solutions. It operates through the following segments: Cloud Services and Colocation Services. The Cloud Services segment offers computing services to support generative AI workstreams. The Colocation Services segment provides customers with physical space, power and cooling within the data center facility. The company was founded on August 15, 2024 and is headquartered in New York, NY.

Whitefiber Inc.

WhiteFiber, Inc.

WhiteFiber is trending after securing a major 10-year, $865 million colocation agreement with Nscale for its NC-1 AI data center, a development the community sees as a long-awaited catalyst to validate the company's business model. Investors are actively discussing the stock's low float, potential for a short squeeze, and the implications of this contract on the company's long-term revenue growth and ability to attract future hyperscale clients.

United Parcel Service, Inc. is a package delivery company, which engages in the provision of global supply chain management solutions. It operates through the following segments: U.S. Domestic Package, International Package, and Supply Chain Solutions. The U.S. Domestic Package segment includes time-definite delivery of letters, documents, and packages. The International Package segment focuses on delivery and shipments in Europe, Asia, the Indian sub-continent, the Middle East, Africa, Canada, and Latin America. The Supply Chain Solutions is involved in forwarding, logistics, Coyote, Marken, and UPS Mail Innovations. The company was founded by James E. Casey and Claude Ryan on August 28, 1907 and is headquartered in Atlanta, GA.

United Parcel Service, Inc. - Ordinary Shares - Class B

United Parcel Service, Inc.

UPS is currently a major focus for traders as the stock attempts a recovery following a multi-year downtrend, with community sentiment split between those viewing it as a deep-value turnaround play and others concerned about long-term margin pressure from labor costs and losing Amazon volume. Investors are actively monitoring the stock's consolidation around the $100 level, looking for signs that restructuring efforts and cost-cutting can successfully defend the dividend and drive a sustained breakout.

Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The firm is also involved in providing sequencing and data analysis services to support population sequencing initiatives. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in February 2011 and is headquartered in Fremont, CA.

Personalis Inc

Personalis Inc. is trending as investors weigh anticipation for upcoming Medicare coverage decisions against volatility driven by recent capital raises and sector-wide sentiment. The community remains focused on the company's long-term potential as a critical player in oncology diagnostics and personalized cancer vaccines, while actively debating the impact of management's communication strategy and the timing of regulatory milestones.

TOSHI

TOSHI is trending as the community debates its potential for a major recovery, with many members actively buying the dip and citing the token's status as a key project on the Base network. While some investors express frustration over price volatility, the conversation is largely driven by long-term holders discussing technical setups, potential exchange listings, and the broader outlook for memecoins.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Novo Nordisk's Pricing Shift Could Unlock a Much Larger Obesity Market

Key PointsThe market for weight loss drugs still has plenty of room to grow...

Novo Nordisk A/S $NVO Stock Position Lifted by Banque Pictet & Cie SA

Banque Pictet & Cie SA grew its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 68.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm...

Novo Nordisk A/S (NYSE:NVO) Receives Average Rating of "Hold" from Brokerages

Shares of Novo Nordisk A/S (NYSE:NVO - Get Free Report) have been assigned an average rating of "Hold" from the twenty-four brokerages that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, nineteen have given a hold rating and fou...

Novo Nordisk (NVO) Rises Higher Than Market: Key Facts

Novo Nordisk (NVO) closed at $36.98 in the latest trading session, marking a +1.37% move from the prior day.

Novo Nordisk A/S (NYSE:NVO) Shares Up 1.2%  - Time to Buy?

Novo Nordisk A/S (NYSE:NVO) Trading 1.2% Higher - Here's Why...

Novo Nordisk claims Wegovy shows greater weight loss than Eli Lilly's rival pill

A cross-trial comparison shows Novo's oral semaglutide produced three percentage points more weight loss and fewer dropouts due to side effects...

LLY Stock Up on GLP-1 Pill Approval: Can it Outpace NVO's Wegovy Pill?

Eli Lilly stock gains on FDA nod for oral obesity drug Foundayo, expanding its portfolio and patient access, setting up a fresh showdown with Novo Nordisk in the GLP-1 market.

<ul class="summary-bullets"><li>Results from the ORION study showed that using semaglutide led to about 3 percentage points more weight loss on average.</li><li>In a separate patient survey, 84% of participants preferred a treatment profile similar to semaglutide over orforglipron, Novo said.</li><li>The study used a population-adjusted indirect treatment comparison to measure weight loss and tolerability between oral semaglutide 25 mg and orforglipron 36 mg.</li></ul>Novo Nordisk (NVO) on Thursday said that oral semaglutide 25 mg delivered greater weight loss than orforglipron, just a day after the U.S. Food and Drug Administration <a href="https://stocktwits.com/news-articles/markets/equity/lly-stock-rallies-on-much-awaited-fda-approval-for-weight-loss-pill/cZ7Hp5ORIF5">approved</a> Eli Lilly’s weight loss drug.<a href="https://stocktwits.com/symbol/NVO">NVO stock</a> was little changed at the time of writing while <a href="https://stocktwits.com/symbol/LLY">LLY shares</a> fell more than 1%.Results from the ORION study showed semaglutide led to about 3 percentage points more weight loss on average, Novo said. The FDA approved orforglipron at doses up to 17.2 mg. The approved 17.2 mg tablet is equivalent to the 36 mg capsules used in Phase 3 trials, which were used as the comparator in the ORION study.The ORION study used a population-adjusted indirect treatment comparison to measure weight loss and tolerability between oral semaglutide 25 mg and orforglipron 36 mg. It was based on data from the Phase 3 OASIS 4 and ATTAIN-1 clinical trials.<h2 class="st-heading-2">Discontinuation Rates Roughly 14 Times Higher With orforglipron</h2>The study also found tolerability advantages for semaglutide. Patients taking orforglipron had significantly higher odds of stopping treatment due to side effects, especially gastrointestinal (GI) issues. Discontinuation rates due to GI events were roughly 14 times higher with orforglipron.In a separate patient survey, 84% of participants preferred a treatment profile similar to semaglutide over orforglipron.<h2 class="st-heading-2">Novo’s Discounted Offering&nbsp;</h2>Earlier this week, Novo Nordisk&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-offers-discounted-subscription-plan-for-us-patients-using-wegovy/cZEPHskRIVf">introduced&nbsp;</a>a discounted subscription plan for U.S. patients paying out of pocket for its obesity drug Wegovy, aiming to better compete with Eli Lilly.&nbsp;Monthly pricing for Wegovy injections now ranges from $329 for a three-month plan to $249 for a one-year plan, compared with the usual $349, while the pill version is priced between $249 and $289 per month.By comparison, Eli Lilly’s self-pay pricing for Zepbound starts at $299 per month for the 2.5 mg dose and increases to $399 for 5 mg, $449 for 7.5 mg, with higher doses priced further up.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment for NVO on Stocktwits remained in the ‘bearish’ territory over the past 24 hours.One&nbsp; user said Novo’s data was a “big distortion.”<stembedurl>https://stocktwits.com/stockanalyst8/message/649299985</stembedurl>However, another user said that the latest data “could&nbsp;limit sales for orforglipron.<stembedurl>https://stocktwits.com/MStocktwit/message/649293749</stembedurl>Year-to-date the NVO shares have declined nearly 30% while LLY stock has shed more than 13%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a Novo Nordisk logo is displayed on a smartphone with stock market percentages in the background. (Photo Illustration by Omar Marques/SOPA Images/LightRocket via Getty Images)

Novo Nordisk Highlights Semaglutide Edge A Day After FDA Clears Lilly’s Orforglipron

The study also showed discontinuation rates due to gastrointestinal events were roughly 14 times higher with orforglipron.

GLP-1 Rivalry Heats Up: Novo Nordisk Claims Lead Over Lilly’s Newly Approved Pill

Equity

Novo Nordisk says Wegovy pill outperforms Lilly's oral GLP-1 in cross-trial comparison

Novo and Eli Lilly are both trying to shape the narrative of their rival pills, considered to be the start of the next phase of the weight-loss drug era...

Lilly (LLY) Surges 3.8%: Is This an Indication of Further Gains?

Lilly (LLY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

Stocktwits

Stocktwits Polls

Novo Nordisk A/S

Traders are fiercely debating the efficacy and convenience of new oral weight-loss pills as Novo Nordisk and Eli Lilly compete for market dominance.

Many investors view the stock's significant decline to 52-week lows and low P/E ratio as a massive buying opportunity rather than a permanent loss.

A divide has emerged between long-term holders focused on drug fundamentals and shorts betting that recent competitive setbacks will drive prices lower.

NVO
Novo Nordisk A/S

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest NVO News

NVONovo Nordisk A/S